



শফিক বসাক এন্ড কোং  
**SHAFIQ BASAK & CO.**  
CHARTERED ACCOUNTANTS



INDEPENDENT MEMBER OF  
**ABACUS**  
WORLDWIDE



**PRIVATE & CONFIDENTIAL**

**DHAKA OFFICE :**

SHATABDI CENTRE (6<sup>TH</sup> FLOOR)  
292, INNER CIRCULAR ROAD,  
FAKIRAPOOL, MOTIJHEEL, DHAKA, BANGLADESH  
Mobile : +8801713375001  
Pho/Fax : 88-02-7192098  
E-mail : ashraf\_shafiqbasak@yahoo.com  
ashraf.icab06@gmail.com  
Web : www.shafiqbasak.com

**CHATTOGRAM OFFICE:**

NATIONAL HOUSE (1st FLOOR)  
109, AGRABAD COMMERCIAL AREA  
CHATTOGRAM-4100, BANGLADESH.  
Phone : 88-031-711561  
Pho/Fax : 88-031-723680  
Email : basak\_sbc@yahoo.com  
basak@shafiqbasak.com  
Web : www.shafiqbasak.com

**INDO-BANGLA PHARMACEUTICALS PLC.**

**Financial Statements**

**For the year ended June 30, 2025**

**INDO-BANGLA PHARMACEUTICALS PLC.**  
**Financial Statements**  
**For the year ended June 30, 2025**

**TABLE OF CONTENT**

<b>SL #</b>	<b>PARTICULARS</b>	<b>PAGE #</b>
01	Auditor's Report	1-4
02	Statements of Financial Position	5
03	Statements of Profit or Loss and Other Comprehensive Income	6
04	Statement of Changes in Equity	7
05	Statement of Cash Flows	8
06	Notes to the Financial Statements & Annexures	9-26



INDEPENDENT AUDITORS' REPORT  
TO THE SHAREHOLDERS OF  
INDO-BANGLA PHARMACEUTICALS PLC.

**Qualified Opinion**

We have audited the financial statements of **Indo-Bangla Pharmaceuticals PLC.** (the Company), which comprise the statement of financial position as at 30 June 2025 along with the statement of profit or loss and other comprehensive income and statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, except for the effects of the matters describe in the basis of qualified opinion section of our report the accompanying financial statements of the Company present fairly of the financial position of the Company as at 30 June 2025 and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs) the company act 1994 and security exchange rules 2020 and other applicable laws and regulations.

**Basis for Qualified Opinion**

**1. Note: 5.00 Capital Work in Progress: Taka 33,221,547.00**

No verifiable proof or supporting documentation was provided to confirm the existence of the Capital Work in Progress (CWIP) amounting to Taka 33,221,547.00 as well as transferred to Fixed Assets to the amount Taka 6,059,503.00. Accordingly, we could not obtain reasonable assurance regarding the existence and valuation of the CWIP reported in the financial statements.

**2. Note No. 6.00 Inventories: Tk. 103,569,933.00**

- The **Finished Goods Register** has not been properly maintained. Certain entries were omitted, such as the item "Calfresh – M Tablet" (Quantity: 37,050 units; Value: Taka 7,780,500) for the year ended 30 June 2025.
- The **Work-in-Process (WIP)** records were found to be maintained only in an Excel worksheet. No formal WIP register for the year ended 30 June 2025 was available for verification.
- Costing of raw materials, finished goods, work in process have not been provided to us. So, we could not conform the compliance of IAS-2.

**3. Note No. 9.00 Cash and Cash equivalents: Tk. 4,342,975.00**

The bank book/ registers have not been provided to us for verification. Consequently, we were unable to obtain sufficient and appropriate audit evidence regarding bank transactions and balances, and could not verify the same reported in the financial statements.

**4. Note No. 18.00 Sales Revenue: Tk. 184,177,513.00**

Particulars	Taka
Gross Sales	211,804,140.00
Less: VAT	27,626,627.00
<b>Net Sales Revenue</b>	<b>184,177,513.00</b>

- Gross Sales for the year were reported at Taka 211,804,140, while total bank deposits recorded amounted to Taka 151,135,367. A material difference of Taka 60,668,773 exists between the total sales and bank deposits, and clarification for this variance was not provided.
- Additionally, VAT returns against sales and VAT deposits to the government treasury were not provided.

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled

our other ethical responsibilities by these ethical requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

#### **Emphasis of Matter**

- a) The books of accounts and ledgers related to the financial statements should be maintained in a proper manner. Instead, they are being maintained through Excel worksheets, which may not ensure adequate accounting control or accurate reflection of transactions in the financial statements.
- b) **Note No. 3.00 Property, Plant & Equipment: Tk. 1,264,563,706.00**  
Fixed Register has been prepared during the year 2024-2025. it was noted that supporting evidence relating to land development costs was not preserved by the company.
- c) **Note No. 14.00 Unclaimed Dividend: Tk. 14,8000,807.00**  
The above amount includes Taka 14,813,593.00 relating to the years 2018–2019 to 2021–2022. This represents a significant issue, as the Company is required, under the directives of the Bangladesh Securities and Exchange Commission, to transfer any funds that remain unpaid, unclaimed, or unsettled for a period of three years.

#### **Material uncertainty related to going concern**

The Company has incurred losses of Taka 36,831,741.00 for the year 2024–2025 and Taka 40,979,225.00 for the year 2023–2024. In addition, we have observed inadequacies in internal control and record-keeping. Furthermore, the Company's financial stability and liquidity are insufficient to withstand unforeseen crises. These conditions indicate the existence of a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern in the foreseeable future.

We conducted our audit in accordance with International Standards on Auditing (ISAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

#### **Other Information**

The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. We have not been provided the Director's report and other information contained within the annual report except the financial statements to the date of our auditor's report. We expect to obtain the remaining reports of the Annual report after the date of our auditor's report. Management is responsible for the other information.

In connection with our audit of financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Our opinion on the financial statements does not cover other information and we do not express form of assurance conclusion thereon.

#### **Responsibilities of Management and Those Charged with Governance for the Financial Statements**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards (IFRSs) the companies act 1994, the security exchange rules 2020 and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.



In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those charged with governance are responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with International Standards on Auditing (ISAs), we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the company's financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a manner should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication. We have not come across any other key audit issue for the year under audit, and as such nothing is reportable.



### Report on other Legal and Regulatory Requirements

In accordance with the Companies Act, 1994 and the Securities and Exchange Rules 2020, we also report the following:

- a) We have obtained all the available information and explanations which to the best of our knowledge and belief was necessary for the purposes of our audit and made due verification thereof;
- b) In our opinion, available books of account as required by law have been kept by the Company so far as it appeared from our examination of those books;
- c) The statement of financial position and statement of profit or loss and other comprehensive income together with the annexed notes dealt with by the report are in agreement with the available books of account and returns; and
- d) The expenditure incurred was assumed for the purposes of the company's business.

Date: December 08, 2025  
Dhaka

  
Md. Ashraful Haque FCA  
Enrolment # 0976  
Partner  
Shafiq Basak & Co.  
Chartered Accountant  
DVC: 2512080976AS999861





**INDO-BANGLA PHARMACEUTICALS PLC**  
**STATEMENT OF FINANCIAL POSITION**  
As at 30 June, 2025

Particulars	Notes	Amounts in Taka	
		30 June 2025	30 June 2024
<b>ASSETS:</b>			
<b>Non-current Assets:</b>		<b>1,298,261,253</b>	<b>1,326,160,930</b>
Property, Plant and Equipment	3.00	1,264,563,706	1,286,879,880
Intangible Assets	4.00	476,000	-
Capital Work In Progress	5.00	33,221,547	39,281,050
<b>Current Assets:</b>		<b>425,847,942</b>	<b>495,939,118</b>
Inventories	6.00	103,569,933	161,590,782
Trade & Other Receivables	7.00	196,238,245	202,261,327
Advance, Deposits and Prepayments	8.00	121,696,790	121,691,581
Cash and Cash equivalents	9.00	4,342,975	10,395,428
<b>TOTAL ASSETS</b>		<b>1,724,109,195</b>	<b>1,822,100,048</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Shareholders' Equity:</b>		<b>1,456,282,610</b>	<b>1,580,842,948</b>
Share Capital	10.00	1,162,051,780	1,162,051,780
Retained Earnings	11.00	294,230,830	418,791,168
<b>NON-CURRENT LIABILITIES</b>		<b>150,241,186</b>	<b>141,103,996</b>
Deferred Tax Liability	12.00	150,241,186	141,103,996
<b>Current Liabilities:</b>		<b>117,585,399</b>	<b>100,153,105</b>
Short Term Loan	13.00	20,000,000	24,200,000
Unclaimed Dividend	14.00	14,800,807	14,813,593
Trade Payables and Other Payable	15.00	18,473,871	855,971
Provision for Taxes	16.00	51,828,396	49,966,641
Liabilities for Expenses	17.00	12,482,325	10,316,900
<b>Total Liabilities</b>		<b>267,826,586</b>	<b>241,257,101</b>
<b>TOTAL OWNER'S EQUITY AND LIABILITIES</b>		<b>1,724,109,195</b>	<b>1,822,100,048</b>
<b>Net Asset Value (NAV) Per Share</b>	<b>26.00</b>	<b>12.53</b>	<b>13.60</b>

Annexed notes form an integral part of these financial statements.



**Chief Financial Officer**      **Company Secretary**      **Director**      **Managing Director**

Signed in terms of our separate report of even date.

Date: December 08, 2025  
Dhaka

  
**Md. Ashraful Haque FCA**  
Enrolment # 0976  
Partner  
**Shafiq Basak & Co.**  
Chartered Accountants  
DVC: 2512080976AS999861



**INDO-BANGLA PHARMACEUTICALS PLC**  
**STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**  
For the year ended 30th June, 2025


Particulars	Notes	Amount In BDT	
		30 June 2025	30 June 2024
Net Sales Revenue	18.00	184,177,513	176,642,457
Less: Cost of Sales	19.00	163,154,222	156,791,702
<b>Gross Profit</b>		<b>21,023,291</b>	<b>19,850,755</b>
<b>Less: Operating Expenses:</b>		<b>46,955,986</b>	<b>48,013,667</b>
Administrative Expenses	20.00	29,859,919	35,836,079
Financial Expenses	21.00	1,872,462	4,403,049
Selling & Distributing Expenses	22.00	15,223,605	7,774,539
<b>Profit from Operations</b>		<b>(25,932,695)</b>	<b>(28,162,913)</b>
Add: Non Operating Income:	23.00	99,900	253,810
<b>Profit before Contribution to WPPF &amp; Welfare Fund</b>		<b>(25,832,795)</b>	<b>(27,909,103)</b>
Less: Contribution to WPPF & Welfare Fund		-	-
<b>Profit before Tax</b>		<b>(25,832,795)</b>	<b>(27,909,103)</b>
<b>Less: Income Tax Expenses:</b>		<b>10,998,946</b>	<b>13,070,122</b>
Current Tax	24.00	1,861,755	1,110,616
Deferred Tax	12.00	9,137,191	11,959,506
<b>Net Profit for the year</b>		<b>(36,831,741)</b>	<b>(40,979,225)</b>
<b>Earnings per share (EPS)</b>	25.00	<b>(0.32)</b>	<b>(0.35)</b>

Annexed notes form an integral part of these financial statements.

  
Financial Officer


  
Company Secretary

  
Director

  
Managing Director

Signed in terms of our separate report of even date.

Date: December 08, 2025  
Dhaka

  
Md. Ashraful Haque FCA  
Enrolment # 0976  
Partner  
Shafiq Basak & Co.  
Chartered Accountants  
DVC: 2512080976AS999861



**INDO-BANGLA PHARMACEUTICALS PLC**

**Statement of Changes In Equity**

For the year ended 30th June, 2025

Particulars	Share Capital	Retained Earnings	Total Equity
Balance as at 01-07-2024	1,162,051,780	418,791,168	1,580,842,948
Issue of share Capital (Bonus)	-	-	-
Prior year adjustment		(86,566,545)	(86,566,545)
Cash Dividend	-	(1,162,052)	(1,162,052)
Net Profit for the period	-	(36,831,741)	(36,831,741)
Balance as at 30-06-2025	1,162,051,780	294,230,830	1,456,282,610

**INDO-BANGLA PHARMACEUTICALS PLC**

**Statement of Changes in Equity**


For the year ended 30th June 2024


Particulars	Share Capital	Retained Earnings	Total Equity
Balance as at 01-07-2023	1,162,051,780	459,770,393	1,621,822,173
Issue of share Capital (Bonus)	-	-	-
Cash Dividend			
Net Profit for the period	-	(40,979,225)	(40,979,225)
Balance as at 30-06-2024	1,162,051,780	418,791,168	1,580,842,948

Annexed notes form an integral part of these financial statements.

  
Chief Financial Officer

  
Company Secretary

  
Director

  
Managing Director

Date: 08 December 2025  
Dhaka



**INDO-BANGLA PHARMACEUTICALS PLC**

Statement of Cash Flows


For the year ended 30th June, 2025

Particulars	Notes	Amount in Taka	
		30 June 2025	30 June 2024
<b>Cash Flows from Operating Activities</b>			
Cash receipts from customers	28.00	190,200,595	198,031,927
Cash receipts from others income	29.00	99,900	253,810
Cash payment to Suppliers	30.00	(48,289,278)	(99,918,204)
Cash payment to Employees		(34,333,397)	(32,967,060)
Cash payment to Others		(49,228,891)	(26,640,509)
<b>Cash Generate from operation</b>		<b>58,448,929</b>	<b>38,759,964</b>
Cash payment against income Tax		-	(4,991,166)
<b>Net Cash generated from Operating Activities</b>	<b>31.00</b>	<b>58,448,929</b>	<b>33,768,798</b>
<b>Cash Flow from Investing Activities</b>			
Acquisition of property, plant and equipment		(560,000)	-
Paid for Capital Work In Progress		-	(10,131,097)
<b>Net Cash used in Investing Activities</b>		<b>(560,000)</b>	<b>(10,131,097)</b>
<b>Cash Flows from Financing Activities</b>			
Short Term Loan		(4,200,000)	(19,410,000)
Paid for Interest on Loan		(1,872,462)	(4,850,036)
Paid for other financing activities		(56,706,868)	-
Paid for Dividend Previous Year		(1,162,052)	(286,021)
<b>Net Cash Used in Financing Activities</b>		<b>(63,941,382)</b>	<b>(24,546,057)</b>
<b>Net increase/(Decrease) in Cash and Cash equivalents</b>		<b>(6,052,453)</b>	<b>(908,357)</b>
Cash and Cash Equivalents at beginning of the period		10,395,428	11,303,785
Cash and Cash Equivalents on Dividend Accounts		-	-
<b>Cash and Cash Equivalent at end of the Period</b>		<b>4,342,975</b>	<b>10,395,428</b>
<b>Net Operating Cash Flows Per Share (NOCFPS)</b>		<b>0.50</b>	<b>0.29</b>

Annexed notes form an integral part of these financial statements.

  
Chief Financial Officer

  
Company Secretary

  
Director

  
Managing Director

Date: 08 December 2025  
Dhaka



**INDO-BANGLA PHARMACEUTICALS PLC.**  
Notes to the Financial Statements and other explanatory information.  
As at and for the year ended June 30, 2025

**1.00 REPORTING ENTITY**

**1.01 Background of the Company**

Indo-Bangla Pharmaceuticals Limited was incorporated as a private Limited Company under the Companies Act-1994 on 18 June 2014 vide registration no.C-116665/14 through takeover of M/S, Indo-Bangla Pharmaceutical Works, a proprietorship business since pre-liberation period. The company has been converted into public limited company on 21-10-2014. Registered office of the company and Factory is at Aziz Bhaban, College Road, Barisal. Authorized capital of the company is Tk.1, 500,000,000 divided into 150,000,000 ordinary shares of Tk.10 each. Paid up capital of the company Tk.1,162,051,780 divided into 116,205,178 ordinary shares of Tk. 10 each.

**1.02 Registered Office of the Company**

The registered office of the Company and the Factory is located at 729, College Road, Barisal Sadar, Barisal and having its corporate office at Polt-183 (7 floor) Block-B, Ahmed Akbar Sobhan Road, Basundhara R/A, Baridhara, Dhaka-1229.

**1.03 Nature of the business**

The Company is engaged in manufacturing and selling of all kinds of medicine (excluding Antibiotic), medical preparations drugs & chemicals (Human Health) with due approval of Drug Administration Authority. The company applied for permission for production and selling of veterinary medicine also.

**2.00 BASIS OF PREPARATION AND PRESENTATION OF FINANCIAL STATEMENTS:**

**2.01 Presentation of Financial Statements**

The Financial Statements of the Company are prepared on a going concern Basis under historical cost convention and in accordance with the International Accounting Standards (IAS), International Financial Reporting Standards (IFRS), the Companies Act, 1994, the Securities and Exchange Rules, 2020 and other laws & regulation in Bangladesh applicable to the Company.

**2.02 Going Concern**

The company has adequate resources to continue its operation for the foreseeable future. The current credit facilities and resources of the company provides sufficient fund to meet the present requirements of its existing business. As such, the directors intended to adopt the going concern Basis in preparing the financial statements.

**2.03 Accrual Basis**

The financial statements have been prepared, except Statements of Cash Flows, using the accrual Basis of accounting.

**2.04 Reporting Period**

The financial Statements have been prepared covering one year from July 01, 2024 to June 30, 2025.

**2.05 Components of the Financial Statements**

According to IFRS-1 "presentation of the Financial Statements" the complete set of financial statements includes the following components;

- a) Statement of Financial Position as at June 30, 2025;
- b) Statement of Profit or Loss and other Comprehensive Income for the period from 1<sup>st</sup> July 2024 to 30 June, 2025;
- c) Statement of Changes in Equity for the year ended June 30, 2025;
- d) Statement of Cash Flows for the year ended June 30, 2025; and
- e) Notes comprising a summary of significant accounting policies and other explanatory information.

**2.06 Accounting Policies & Estimates**

The preparation of these financial statements is in conformity with IAS and IFRS which require management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Estimates and



underlying assumptions are reviewed on an ongoing basis and used for accounting of certain terms such as provision for expenses and depreciation.

## 2.07 Responsibility for Preparation and Presentation of Financial Statements

The Board of Directors is responsible for the preparation of financial statements under section 183 of the Companies Act, 1994 and as per the provision of "the Framework for the preparation and Presentation of Financial Statements" issued by the International Accounting Standards (IASs) and Bangladesh Securities and Exchange Commission (BSEC) guideline.

## 2.08 Statement of Cash flows

Statement of Cash flows have been prepared in accordance with IAS-7 "Statement of Cash Flows" and the cash flows from the operating activities have been presented under direct method considering the provisions of Paragraph 19 of IAS-7 which provides that "Entities are encouraged to report cash flows from operating activities using the direct method".

## 2.09 Applicable accounting standards

The following IAS and IFRS are applicable for the financial statements for the year under review:

### IASs & IFRSs:

IAS-1	Presentation of Financial Statements
IAS-2	Inventories
IAS-7	Statements of Cash flows
IAS-8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS-10	Events after the Reporting Period
IAS-12	Income Taxes
IAS-16	Property, Plant and Equipment
IAS-19	Employee Benefits
IAS-24	Related Party Disclosures
IAS-32	Financial Instruments Presentation
IAS-33	Earnings Per Share
IAS-36	Impairment of Assets
IAS-37	Provisions, Contingent Liabilities and Contingent Assets
IFRS 7	Financial Instruments: Disclosures
IFRS 8	Operating Segments
IFRS 9	Financial Instruments
IFRS 15	Revenue from Contracts with Customers
IFRS 16	Lease;

## 2.10 Property, Plant and Equipment

### 2.10.1 Recognition and Measurement

All Property, Plant and Equipment are stated at cost less accumulated, depreciation as per IAS- 16 "Property, Plant and Equipment". The cost of acquisition of an asset comprises of its purchase price and any directly attributable cost of bringing the asset to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes.

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its costs can be measured reliably. The cost of the day to day maintaining cost on PPE is recognized in the Statements of Profit or Loss and other Comprehensive Income as incurred.

### 2.10.2 Depreciation

Depreciation on Property, Plant and Equipment other than Land has been computed during the year using the reducing balance method. Depreciation has been charged on addition when the related Property, Plant and Equipment are available for use as per management intention. Depreciation has been charged at following rates:

Name of Assets	Rate	
	As at 30 June 2025	As at 30 June 2024
Land and Land Development	0%	0%
Building	2.50%	2.50%
Civil Works	5%	5%



Machineries & Equipment	2%	3%
Micro biological Lab	3%	3%
Factory Air Condition	10%	10%
Generator	3%	3%
Sub-Station (electricity) 630 KVA	10%	10%
Furniture & Fixture	10%	10%
Office Equipment SEP Decoration	10%	10%
Office Decoration	10%	10%
Computer	10%	10%
Air Condition	10%	10%
Transport	10%	10%
Water Plant	10%	10%
ETP Plant	10%	10%

### 2.10.3 Retirement and Disposals

An asset is derecognized on disposal or when no future economic benefits are expected from its use and subsequent disposal. Gain or loss arising from the retirement or disposal of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the assets and is recognized as gain or loss from disposal of asset under other income in the statement of profit or loss and other comprehensive income.

### 2.10.4 Impairment

All fixed assets have been reviewed and it was confirmed that no such fixed assets have been impaired during the period and for this reason no provision has been made for Impairment of assets as per IAS 36.

### 2.11 Revenue Recognition

As per IFRS-15: "Revenue from Contracts with Customers" the company accounts for a contract with a customer only when all of the following criteria are met:

- The parties to the contract have approved the contract (in writing, orally or in accordance with other customary business practices) and are committed to perform their respective obligations;
- The company can identify each party's rights regarding the goods or services to be transferred;
- The company can identify the payment terms for the goods or services to be transferred
- The contract has commercial substance (i.e., the risk, timing or amount of the entity's future cash flows is expected to change as a result of the contract); and
- It is probable that the company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.

### 2.12 Valuation of Current Assets

#### Trade and Other Receivable

These are carried forward at their original invoiced value amount and represents net realizable value. Management considered the entire bills receivable as good and is collectable and therefore, no amount has been provided for as bad debt in the current year's account.

#### Inventories

In compliance with the requirements of IAS-2 "Inventories", the Inventories have been valued at Cost or Net Realizable value whichever is lower, which is consistent with the previous period's practice. Net realizable value is based on estimated selling price in the ordinary course of business less any further cost expected to be incurred to make the sale.

#### Provisions:

Provisions were made considering risk and un-certainties at best estimate of the probable expenditure that would require to meet the current obligation at the date of statement of financial position.

### 2.14 Employees' Benefit

The company maintains defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective deeds.

The company has accounted for and disclosed employee benefits in compliance with the provisions of IAS 19: "Employee Benefits",



The cost of employee benefit is charged off as revenue expenditure in the year to which the contributions relate. The company's employee benefits include the following.

**a) Short Term Employee Benefit**

Short-term employee benefits include wages, salaries, festival bonuses etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

**b) Contribution to Workers' Profit Participation and Welfare Funds**

This represents 5% of net profit before tax but after charging such expenses by the company as per provisions of the Bangladesh Labor Act, 2006, & Bangladesh Labor (amendment) Act, 2013.

**c) Post Employment Benefit**

The Nomination and Remuneration Committee (NRC), a sub-committee of Board formed to ensure good governance in the company as per Corporate Governance Code in notification No. BSEC/CMRRCD/2006 of Bangladesh Securities and Exchange Commission reviewed all post employee benefits to comply with IAS 19.

**2.15 Advances, Deposits and Prepayments**

Advances are initially measured at cost. After initial recognition advances are carried at cost less deductions, adjustments or charges to other account heads such as PPE of Inventory etc.

**2.16 Functional and Presentational Currency:**

The financial statements are prepared in Bangladeshi Taka which is the Company's functional currency.

**2.17 Income Tax Expenses:**

Income Tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to items recognized directly in equity and profit or loss.

**Current Income Tax**

Current income tax is excepted tax payable on the taxable income for the year and any short fall of provision for previous years. The company (IBPL) is a "Publicly Traded Company"; hence Tax rate is applicable @ 20%.

**Deferred Tax**

Deferred tax expenses are considered for taxable temporary differences may arise for the reporting year, adjustments for prior years accumulated differences and changed in tax rate.

**2.18 Earnings per Share**

The company calculates Earnings per Share (EPS) in accordance with IAS-33 "Earnings per Share" which has been shown on the face of the Profit or Loss and other Comprehensive Income,

**Basic Earnings**

This represents profit or loss at the end of the period attributable to ordinary shareholders of the entity.

**Basic Earnings per Share**

This has been calculated by dividing profit or loss attributable to ordinary shareholders of the entity by the weighted average number of ordinary shares outstanding during the year.

**2.19 Financial Instruments**

A financial instrument is any contract that gives rise to a financial asset to one entity and a financial liability or equity instrument to another entity as per IAS-32 "Financial Instruments Recognition and Measurement."

**Financial Assets**

Financial assets of the company include cash and cash equivalents, Trade receivables and other receivables. The company initially recognizes a financial asset in its statement of financial position when, and only when, the company becomes a party to the contractual provision of the instrument. The company derecognizes a financial asset when, and only when; the contractual rights to the cash flows from the financial asset expire or transfer the contractual rights to receive the cash flows of the financial asset.



## **Financial Liabilities**

Financial liabilities of the company include trade payables and liabilities for expenses. The company initially recognizes a financial liability in its statement of financial position when, and only when, the company becomes a party to the contractual provision of the instrument. The company derecognizes a financial liability from its statement of financial position when, and only when, it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires.

### **2.20 Cash and Cash Equivalents**

According to IAS-7 'Statement of Cash Flows', cash comprises cash in hand, short term deposit and highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in values.

### **2.21 Events after the Reporting Period**

Events after the reporting period are those events, favorable and unfavorable, that occur between the end of the reporting period and the date when the financial statements are authorized for issue. Two types of events can be identified:

Adjusting Events are those that provide evidence of conditions that existed at the end of the reporting period. Non-adjusting Events are those that are indicative of conditions that arose after the reporting period.

### **2.22 Authorization date for issuing Financial Statements**

The financial statements were authorized by the Board of Directors on November 15, 2025.

### **2.22 Comparative Information**

Comparative Information has been disclosed in the respect of previous year for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year's financial statement.

### **2.23 Re-arrangement**

Previous year figure has been re-arranged whenever considered necessary to ensure comparability with the current year presentation as per IAS-8: "Accounting Policies, Changes in Accounting Estimates and Errors".

#### **Re-Statement**

In finalizing the financial statements for the year ended June 30, 2023 some figures of previous year were restated to confirm the provisions of IAS-8: "Accounting Policies, Changes in Accounting Estimates and Errors". During the year the following accounting errors has been rectified in compliance with IAS -8.

### **2.24 Segmental Reporting**

The company essentially provides similar products to customers across the country and the products essentially have the similar risk profile. As there is a single business and geographic segment within which the company operates as such no segment reporting is felt necessary.

### **2.25 Related Party Disclosure**

The company carried out a number of transactions with related parties in the normal course of business and on arms' length basis. The information as required by IAS-24: Related Party Disclosures has been disclosed in a separate note to the financial statements.

**2.26 IFRS 16:** Leases introduces a single, on-balance sheet lease accounting model for lessees. A lessee recognizes a right-to-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. There are recognition exemptions for short-term leases and leases of low-value items. Lessor accounting remains similar to the current standard- i.e. lessors continue to classify leases as finance or operating leases. The standard is effective for annual periods beginning on or after 1 January 2019, but also with permission for early adoption.

### **2.27 General**

The figure has been rounded off to the nearest taka.



**Indo-Bangla Pharmaceuticals PLC**  
**Notes to the Financial Statements**  
As at and for the year ended 30 June 2025

Sl.No.	Particulars	Amount in Taka	
		30 June'2025	30 June'2024
<b>3.00</b>	<b>Property, Plant and Equipment</b>		
	(A) At Cost		
	Opening balance	1,514,436,616	1,514,436,616
	Add: Addition during the Period	6,059,503	-
	Less: Disposal during the Period	-	-
	<b>Total</b>	<b>1,520,496,119</b>	<b>1,514,436,616</b>
	(B) Accumulated Depreciation		
	Opening balance	227,556,736	199,013,270
	Add: Depreciation Charged for the period	28,375,677	28,543,466
	Less: Adjusted during the period	-	-
	<b>Total :</b>	<b>255,932,413</b>	<b>227,556,736</b>
	<b>WDV as on 30.06.2025 (a-b)</b>	<b>1,264,563,706</b>	<b>1,286,879,880</b>
	A schedule of Property, Plant and Equipment is given in Annexure-A		
<b>4.00</b>	<b>Intangible Assets</b>		
	(A) At Cost		
	Opening balance	-	-
	Add: Addition during the Period	560,000	-
	Less: Disposal during the Period	-	-
	<b>Total</b>	<b>560,000</b>	<b>-</b>
	(B) Amortization		
	Opening balance	-	-
	Add: Charged for the period	84,000	-
	Less: Adjusted during the period	-	-
	<b>Total :</b>	<b>84,000</b>	<b>-</b>
	<b>WDV as on 30.06.2025 (a-b)</b>	<b>476,000</b>	<b>-</b>
	A schedule of Intangible Assets is given in Annexure-A		
<b>5.00</b>	<b>Capital Work In Progress</b>		
	<b>A. Machineries &amp; Equipment:</b>		
	Opening balance:	23,090,450	23,090,450
	Add: Addition during the year	-	-
	Less: Transfer to Fixed Assets	-	-
	<b>Closing Plant &amp; Machinery</b>	<b>23,090,450</b>	<b>23,090,450</b>
	<b>B.Civil Works:</b>		
	Opening balance	16,190,600	6,059,503
	Add: Addition during the year (BSCIC Plot)	-	10,131,097
	Less: Transfer to Fixed Assets	(6,059,503)	-
		<b>10,131,097</b>	<b>16,190,600</b>
	<b>Total (A+B)</b>	<b>33,221,547</b>	<b>39,281,050</b>
<b>6.00</b>	<b>Inventories :</b>		
	Raw Material	9,409,207	55,749,179
	Finished Goods	83,126,708	89,534,270
	Work - in - Process	3,002,000	1,896,045
	Maintenance of Machine & Consumable Items	921,933	433,397
	Packing Materials	7,110,085	13,977,891
		<b>103,569,933</b>	<b>161,590,782</b>

Inventories in hand have been valued at lower of cost or/and net realizable value as per IAS-2 and have been certified by management.



Sl.No.	Particulars	Amount in Taka	
		30 June'2025	30 June'2024

**7.00 Trade & Others Receivable:**

**A. Trade Receivable**

Opening balance	202,261,327	223,651,430
Add: Sales during the period	184,177,513	176,642,457
<b>Total</b>	<b>386,438,840</b>	<b>400,293,887</b>
Less: Recovery	190,200,595	198,032,560
<b>Closing balance (Trade Receivable) A schedule of Receivable is given in Annexure-B</b>	<b>196,238,245</b>	<b>202,261,327</b>

**Ageing of Accounts Receivable**

More than six months	39,247,649	67,504,087
Less than six month	156,990,596	134,757,240
<b>Total</b>	<b>196,238,245</b>	<b>202,261,327</b>

The classification of receivables as required by the schedule XI of the Companies Act, 1994 are given

Receivable considered good in respect of which the company is fully secured.	-	-
Receivable considered good in respect of which the company holds no security other than the debtor personal security.	196,238,245	202,261,327
Receivables considered doubtful bad.	-	-
Receivable due by directors or others or other offers of the company or any of them either severly or jointly with any other person or debts due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
Receivables due by common under the same management.	-	-
The maximum amount of receivable due by any director or other officer of the company at any time during the period.	-	-
<b>Total:</b>	<b>196,238,245</b>	<b>202,261,327</b>

**8.00 Advance, deposit and prepayments:**

**Advance**

Advance Income Tax	8.01	45,774,546	45,234,970
Advance to Employees		59,618	2,352,954
Advance to others	8.02	75,862,626	74,103,657
<b>Total</b>		<b>121,696,790</b>	<b>121,691,581</b>

The classification of Advances, Deposits and Prepayments as required by Schedule-XI, Part-I of the

Advance, Deposit and pre-payments considered good and fully secured;	121,696,790	121,691,581
Advance, deposit and pre-payments considered good and company holds no security other than personal security;	-	-
Advance, deposit and pre-payments considered doubtful and bad;	-	-
Advance, deposit and pre-payments due by directors or other officers;	-	-
Advance, deposit and pre-payments due from companies under common management; and	-	-
Maximum advance, deposit and pre-payments due by Directors or other officers at any time.	-	-
<b>Total</b>	<b>121,696,790</b>	<b>121,691,581</b>



Sl.No.	Particulars	Amount in Taka	
		30 June'2025	30 June'2024
<b>8.01</b>	<b>Advance Tax paid</b>		
	Opening	45,234,970	43,847,105
	Add: Tax Paid against Transport	267,000	-
	Add: Tax Paid against Import	272,576	-
	Add: Advance Tax paid during the year	-	1,387,865
	Less: Adjustment During the year for Assessment Year	-	-
		<b>45,774,546</b>	<b>45,234,970</b>
<b>8.02</b>	<b>Advance to Others</b>		
	Goods and services	-	4,238,891
	Tour	-	262,789
	Office Rent	300,000	300,000
	Land (Gazipur)	35,940,000	35,940,000
	Land (BSCIC Barisal)	30,635,000	30,635,000
	L/C Margin for Raw-materials	8,943,562	2,679,000
	Prepaid Insurance	34,578	46,529
	VAT current account	9,486	1,447
		<b>75,862,626</b>	<b>74,103,657</b>
<b>9.00</b>	<b>Cash and Cash equivalents:</b>		
	Cash in Hand	2,672,670	9,956,994
	Cash at Bank	1,652,012	434,846
	Cash at Dividend Bank Accounts	18,293	3,589
		<b>4,342,975</b>	<b>10,395,428</b>
<b>9.01</b>	<b>Cash at Bank</b>		
		<b>1,652,012</b>	<b>434,846</b>
	Pubali Bank Ltd. Barishal Sadar Branch A/C 0374901054490	6,998	47,890
	Sonali Bank Ltd. Barishal Corporate Branch A/C. 03042-13953	5,604	1,825
	Islami Bank Bangladesh Ltd. Barishal Branch A/C no.205011109-10	14,577	15,727
	One Bank Ltd. Barisal Branch A/C no.04903	7,362	-
	Krishi Bank Ltd A/C No-982	2,166	-
	Mutual Trust Bank A/C-80334	1,452,828	-
	Dutch-Bangla Bank Ltd. Barisal Branch A/C 1271100014683	17,997	18,687
	Dutch-Bangla Bank Ltd. Bashundhara 1471100016286	1,411	30,092
	Prime bank A/C no. 16828	9,655	-
	First Security Islami Bank Ltd. Bashundhara Br. A/C 0177111-302	2,863	178,735
	First Security Islami Bank Ltd. Bashundhara Br. A/C 0177111-315	99,645	110,425
	Social Islami Bank Ltd. A/C 077133-6741	-	435
	Eastern Bank Ltd Principal Branch A/C 1011360459420	30,906	31,030
	<b>Dividend Account</b>	<b>18,293</b>	<b>3,589</b>
	First Security Islami Bank Ltd. A/C 0177-31-0040	1,397	2,382
	First Security Islami Bank Ltd. A/C 0177-31-0046	16,896	1,207
<b>10.00</b>	<b>Share Capital :</b>		
	<b>Authorized Capital</b>		
	150,000,000 Ordinary Shares		
	of Tk. 10 each	<b>1,500,000,000</b>	<b>1,500,000,000</b>
	<b>issued, Subscribed &amp; Paid-up Capital:</b>		
	73,000,000 Ordinary Shares of Tk. 10each	730,000,000	730,000,000
	20,000,000 Shares issued for IPO in 2018	200,000,000	200,000,000
	9,300,000 Bonus Shares issued in 2018	93,000,000	93,000,000
	9,207,000 Bonus Shares issued in 2019	92,070,000	92,070,000
	2,230,140 Bonus Shares issued in 2020	22,301,400	22,301,400
	2,468,038 Bonus Shares issued in 2021	24,680,380	24,680,380
	<b>116,205,178 Ordinary Shares of Tk. 10 each fully paid up.</b>	<b>1,162,051,780</b>	<b>1,162,051,780</b>



Sl.No.	Particulars	Amount in Taka	
		30 June'2025	30 June'2024
<b>11.00</b>	<b>Retained Earnings:</b>		
	Opening balance	418,791,168	459,770,393
	Add :Net Profit for the year	(36,831,741)	(40,979,225)
	Less: Transfer to Share capital	-	-
	Less : Adjustment	(86,566,545)	-
	Less: Cash Dividend	(1,162,052)	-
		<b>294,230,830</b>	<b>418,791,168</b>
<b>12.00</b>	<b>Deferred Tax Liability:</b>		
	Carrying Value of Property, Plant & Equipment (Annexure-A)	1,264,563,705	1,286,879,880
	As Tax Base	513,357,773	581,359,900
	Temporary Difference	<b>751,205,932</b>	<b>705,519,979</b>
	<b>Deferred Tax Liabilities @70%</b>	<b>525,844,152</b>	<b>493,863,995</b>
	Less: Opening Deferred Tax Liability	141,103,996	129,144,490
	Add: Addition during the year Tax Rate Change	-	-
	Add: Sale of Assets Depriation Defferance (B-A) @	-	-
	Deferred Tax Liability/Expenses (Income)	<b>9,137,191</b>	<b>11,959,506</b>
<b>13.00</b>	<b>Short Term Loan:</b>		
	Bai Murabaha (Hypo)	20,000,000	19,900,000
	Bai Murabaha (LTR )	-	4,300,000
	<b>Total:</b>	<b>20,000,000</b>	<b>24,200,000</b>
<b>14.00</b>	<b>Unclaimed Dividend:</b>		
	Dividend payable for the year 2018-2019	2,632,693	2,632,693
	Dividend payable for the year 2019-2020	8,671,594	8,671,594
	Dividend payable for the year 2020-2021	1,029,103	1,029,103
	Dividend payable for the year 2021-2022	2,480,203	2,480,203
	Dividend payable for the year 2023-2024	51,600	-
	Paid during the year	(64,386)	-
		<b>14,800,807</b>	<b>14,813,593</b>
<b>15.00</b>	<b>Trade Payables</b>		
	Trade payable	17,405,594	855,971
	Other Payable 15.01	1,068,277	-
	<b>Closing balance</b>	<b>18,473,871</b>	<b>855,971</b>
<b>15.01</b>	<b>Other Payable</b>		
	Tax Deduction at source	147,977	-
	Other supplier payable	920,300	-
		<b>1,068,277</b>	<b>-</b>



Sl.No.	Particulars	Amount in Taka	
		30 June'2025	30 June'2024
<b>16.00</b>	<b>Provision for Taxes</b>		
	This has been arrived as at under;		
	Balance b/d	49,966,641	52,459,325
	Add: Short Provision	-	-
	Less: Excess Provision	-	-
	Less: Adjusted Income Tax Expenses Assessment year	-	-
	Add : Provision during the year	1,861,755	1,110,617
		<b>51,828,396</b>	<b>53,569,942</b>
	Income Tax Paid during The Year	-	3,603,301
		<b>51,828,396</b>	<b>49,966,641</b>
<b>17.00</b>	<b>Liabilities for Expenses :</b>		
	This consists of the following		
	Telephone Bill	-	115
	Electricity Bill	175,370	280,603
	Office Rent	550,000	-
	Directors Remuneration	4,500,000	250,000
	Salary & Wages	1,884,020	2,133,410
	Gratuity	-	5,503,385
	Regulatory Fees	2,865,911	-
	Land Tax Expense	15,240	-
	Central Depository Bangladesh Limited	212,000	-
	Bangladesh Association of Pharmaceuticals Industry	82,000	-
	Bangladesh Association Public Company	100,000	-
	Galaxy Corporation	70,000	-
	Interest on Short Term Loan	1,740,284	806,940
	Audit Fees	287,500	287,500
	Others	-	1,054,948
		<b>12,482,325</b>	<b>10,316,900</b>



Sl.No.	Particulars	Amount in BDT	
		30 June 2025	30 June 2024
<b>18.00</b>	<b>Net Sales Revenue:</b>		
	Gross Sales	211,804,140	203,138,826
	Less: VAT @ 15%	27,626,627	26,496,369
	<b>Net Sales revenue</b>	<b>184,177,513</b>	<b>176,642,457</b>
<b>19.00</b>	<b>Cost of Sales :</b>		
	Raw Material Consumed	87,532,653	86,398,087
	Add: Work in process (Opening)	1,876,045	2,031,250
	Less: Work in Process (Closing)	3,002,000	1,896,045
	<b>Total Consumption</b>	<b>86,426,698</b>	<b>86,533,292</b>
	Add: Manufacturing Overhead	42,152,959	44,366,116
	Add: Direct expenses	28,732,790	20,387,711
	<b>Cost of Production</b>	<b>157,312,448</b>	<b>151,287,120</b>
	Add: Finished Goods (Opening balance)	89,534,270	95,007,530
	<b>Finished Goods Available</b>	<b>246,846,718</b>	<b>247,194,650</b>
	Less: Finished Goods (Closing)	83,126,708	89,534,270
	Less: Sample Costs	565,788	868,678
	<b>Cost of Sales:</b>	<b>163,154,222</b>	<b>156,791,702</b>
<b>19.01</b>	<b>Material Consumed :</b>		
	Opening balance	55,749,179	61,310,515
	Add: Material Purchased	41,192,681	92,257,098
	Import	6,609,474	22,417,296
	Local	34,583,207	69,839,802
	Less: Closing Materials	9,409,207	55,749,179
	Expire date over destroyed Raw Materials	-	11,420,347
	<b>Total</b>	<b>87,532,653</b>	<b>86,398,087</b>
<b>19.02</b>	<b>Manufacturing Overhead:</b>		
	Salary & Wages	9,610,683	9,922,404
	Cork & Cap	244,600	499,035
	Carton & Label	205,350	716,283
	Hand Glove, Tape, Gum Etc	-	24,915
	Accessories	-	663,070
	Carriage Inward	721,543	449,231
	Water bill	-	5,301
	Factory Rent	975,000	-
	QC and Lab Maintenance	12,700	-
	Washing Expenses	-	7,661
	Maintenance of Machine & Consumable Items	464,024	1,046,373
	Electricity Bill Factory	2,868,323	3,816,777
	Staff Fooding	1,789,080	1,611,272
	Fuel & Oil for Generator	204,298	256,412
	Maintenance of Factory Building	83,280	556,710
	Insurance Expense	239,200	232,538
	Depreciation (Annexure-A)	24,734,878	24,498,134
	<b>Total</b>	<b>42,152,959</b>	<b>44,366,116</b>
<b>19.02.01</b>	<b>Maintenance of Machine &amp; Consumable Items</b>		
	Opening balance	433,397	625,420
	Purchase during the period	952,560	854,350
	Closing Balance	(921,933)	(433,397)
	<b>Total</b>	<b>464,024</b>	<b>1,046,373</b>



Sl.No.	Particulars	Amount in BDT	
		30 June 2025	30 June 2024
<b>19.03</b>	<b>Direct expenses :</b>		
	Delivery Charges	128,718	45,104
	Packing Materials	28,604,072	20,327,987
	Medical Bag Expenses	-	14,620
	<b>Total</b>	<b>28,732,790</b>	<b>20,387,711</b>
<b>19.03.1</b>	<b>Packing Materials</b>		
	Opening balance	13,977,891	18,736,814
	Purchase during the period	21,736,266	15,569,064
	Less: Packing Materials (Closing balance)	(7,110,085)	(13,977,891)
	Consumption	<b>28,604,072</b>	<b>20,327,987</b>
<b>20.00</b>	<b>Administrative Expenses</b>		
	Salary & allowance	13,591,148	10,889,793
	Director Remuneration	3,000,000	3,900,000
	Board Meeting Fee	470,000	570,000
	Travelling & Conveyance	122,709	570,820
	Business Development, Legal Expenses & Others	1,509,138	677,448
	Entertainment	492,246	-
	Office Repair & Maintenance Expense	683,735	-
	Staff Fooding	294,815	369,082
	Office Rent	660,000	759,000
	Printing & Stationery	253,969	460,057
	News Paper & Megazine	127,605	65,661
	Postage, courier & Telegram	17,478	13,694
	License & Renewal Fee	683,255	189,049
	Legal & Professional fees	811,331	-
	Telephone & Mobile Bill	189,450	157,244
	Internet Bill	128,300	120,000
	Audit Fee	287,500	287,500
	Company Secretarial, Regulatory Fee and AGM Expenses	1,292,737	331,607
	Annual Subscription and report fees	389,000	-
	Electricity, Gas & others charge	166,408	180,291
	Maintenance of Transport	172,717	278,430
	Fuel & Oil	602,761	190,809
	Land Tax expenses	15,240	-
	Bank Charge	126,163	50,712
	Others expenses	47,415	309,204
	Expire date over destroyed Raw Materials	-	11,420,347
	Amortization (Annexure-A)	84,000	-
	Depreciation (Annexure-A)	3,640,799	4,045,332
	<b>Total</b>	<b>29,859,919</b>	<b>35,836,079</b>
<b>21.00</b>	<b>Financial expenses</b>		
	Interest On Bai Murabaha (Hypo)	1,872,462	1,927,127
	Interest On Bai Murabaha (LTR)	-	2,475,922
	<b>Total:</b>	<b>1,872,462</b>	<b>4,403,049</b>



Sl.No.	Particulars	Amount in BDT	
		30 June 2025	30 June 2024
<b>22.00</b>	<b>Selling &amp; Distributing Expenses</b>		
	Salary & allowance	3,034,552	4,788,717
	Incentive Bonus	7,847,624	95,580
	Dealer's Commission	174,030	127,690
	Tour and TA & DA of Field Staff	219,107	158,030
	Carriage Outward/ Fuel & oil	1,070,590	712,913
	Packing materials-Selling & Distribution	-	681,173
	Sales Promotion	124,000	100,102
	CSR & Donation Expense	895,120	-
	Garage Rent	61,100	-
	Service Charge Software & Others	156,000	-
	Gift & Presentation	1,040,000	143,130
	Sample expenses	14,863	868,678
	Miscellaneous expenses	578,790	-
	Medical Expense	7,829	-
	Travelling & Conveyance/ Deport Delivery	-	98,526
		<b>15,223,605</b>	<b>7,774,539</b>
<b>23.00</b>	<b>Non Operating Income:</b>		
	Misc Sales	99,900	253,810
		<b>99,900</b>	<b>253,810</b>
<b>24.00</b>	<b>Current Tax:</b>		
	Profit before tax as per account	(25,832,795)	(27,909,103)
	Accounting depreciation	28,375,677	28,543,466
	Tax base depreciation	(74,061,630)	(90,340,994)
	Non Operating Income	(99,900)	(253,810)
	Taxable profit	<b>(71,618,648)</b>	<b>(89,960,440)</b>
	Current Tax @ 1% on Turnover Minimum Tax	1,841,775	1,059,855
	Add: Tax on Non Operating Income @ 20%	19,980	50,762
		<b>1,861,755</b>	<b>1,110,616</b>
<b>25.00</b>	<b>Basic Earnings Per Share :</b>		
	This has been calculated in compliance with the requirements of IAS 33: Earnings Per Share, is the basic		
	The composition of earnings per shares (EPS) is given below:		
	<b>Earnings Per Share (EPS)</b>		
	Net profit for the year	(36,831,741)	(40,979,225)
	Weighted Average number of ordinary shares outstanding	116,205,178	116,205,178
	<b>Earnings Per Share (EPS)</b>	<b>(0.32)</b>	<b>(0.35)</b>
	<b>Weighted Average Number of Shares</b>		
	73000000	73,000,000	73,000,000
	20000000	20,000,000	20,000,000
	9300000	9,300,000	9,300,000
	9207000	9,207,000	9,207,000
	2230140	2,230,140	2,230,140
	2468038	2,468,038	2,468,038
	<b>Weighted Average Number of Shares</b>	<b>116,205,178</b>	<b>116,205,178</b>
<b>26.00</b>	<b>Net Assets Value Per Share :</b>		
	The composition of net assets value per share is given below:		
	Total Assets	1,724,109,195	1,822,100,048
	Less: Non-Current Liabilities + Current Liabilities	267,826,586	241,257,191
	Net Assets Value	1,456,282,609	1,580,842,947
	Number of ordinary shares outstanding	116,205,178	116,205,178
		<b>12.53</b>	<b>13.60</b>
<b>27.00</b>	<b>Net Operating Cash Flows Per Share (NOCFPS)</b>		
	Net Cash from operating activities	58,448,970	33,768,708
	Weighted Average Number of Shares	116,205,178	116,205,178
		<b>0.50</b>	<b>0.29</b>



Sl.No	Particulars	Amounts in Taka	
		30 June 2025	30 June 2024
<b>28.00</b>	<b>Cash receipts from customers</b>		
	Opening receivable	202,261,327	223,651,430
	Add: Sales during the year	184,177,513	176,642,457
	Less: Closing receivable	(196,238,245)	(202,261,327)
		<b>190,200,595</b>	<b>198,032,560</b>
<b>29.00</b>	<b>Cash receipts from others income</b>		
	Misc. Sales	99,900	253,810
		<b>99,900</b>	<b>253,810</b>
<b>30.00</b>	<b>Cash payment to suppliers</b>		
	Purchase (RM,spare,packing)	63,881,507	108,680,512
	Opening Accounts Payable	855,971	832,555
	Closing Accounts Payable	(18,473,871)	(855,971)
	Opening Advance goods	(6,917,891)	(4,236,435)
	Closing Advance goods	8,943,562	6,917,891
	Expire date over destroyed Raw Materials	-	(11,420,347)
		<b>48,289,278</b>	<b>99,918,204</b>
<b>31.00</b>	<b>Reconciliation of Net Profit with cash flows from Operating Activities:</b>		
	<b>Profit before Tax</b>	(25,832,795)	(27,909,103)
	Add: Depreciation on property, plant and equipment	28,459,677	28,543,466
		<b>2,626,882</b>	<b>634,363</b>
	Add/(Less):		
	Add: Decrease in Trade & Other Receivables	6,023,082	21,390,103
	Add: Decrease in Inventories	57,893,890	17,020,747
	Add: Increase in Trade Payables	17,617,900	23,417
	Less: Increase in Liabilities for Expenses	2,165,425	(1,256,218)
	Less: Decrease in Liability for contribution to W.P.P.F	-	(1,228,635)
	Less : Decrease in Advance, Deposit & Prepayments	(5,209)	(4,061,714)
	Add/(Less): Capital expenditures	6,059,503	-
	Add: Paid for Interest on Loan	1,872,462	4,850,035
	Less: adjustment	(35,805,006)	-
	Less: Income Tax Paid	-	(3,603,301)
		<b>55,822,047</b>	<b>33,134,434</b>
		<b>58,448,929</b>	<b>33,768,798</b>

**32.00 Related parties disclosures**

**Key Management Personnel:**

As per Schedule-XI, part-II, Para 4 of the Companies Act, 1994, the profit and loss account will give by way of a note detailed information, showing separately the following payments provided or made during the financial year to the directors, including managing director, the managing agents or manager, if any, by the company, subsidiaries of the company and any other person:-

No.	Particulars	30.06.2025	30.06.2024
(a)	Managerial Allowances paid or payable during the period to the directors, including managing directors, a managing agent or manager;	3,000,000	3,900,000
(b)	Expenses reimbursed to Managing Agent;	Nil	Nil
(c)	Commission or Remuneration payable separately to a managing agent or his associate;	Nil	Nil
(d)	Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company;	Nil	Nil
(e)	The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial period;	Nil	Nil
(f)	Any other perquisite or benefits in cash or in kind stating, approximate money value where applicable;	Nil	Nil
(g)	Other allowances and commission including guarantee commission;	Nil	Nil
(h)	Pensions etc.	-	-
	(i) Pensions;	Nil	Nil
	(ii) Gratuities;	Nil	Nil
	(iii) Payments from a provident funds, in excess of own subscription and interest thereon;	Nil	Nil
	(iv) Compensation for loss of office;	Nil	Nil
	(v) Consideration in connection with retirement from office.	Nil	Nil
(i)	Share Based payments	Nil	Nil

**Related parties Transactions:**



Sl.No	Particulars	Amounts in Taka	
		30 June 2025	30 June 2024

The company carried out a number of transactions with related parties. The following are the related parties transactions of the Indo-Bangla Pharmaceuticals Ltd has been disclosed as required by IAS 24 Related Party Disclosures.

(a) Remuneration				
Name	Designation	Nature of Transaction	Amount in (BDT)	
			2024-2025	2023-2024
Mr. A F M Anwarul Huq	Managing Director	Remuneration	3,000,000	3,000,000

(b) Board Meeting fee

Name	Designation	Nature of Transaction	Amount in (BDT)	
			2024-2025	2023-2024
Ms. Ayesha Siddika	Chairman	Board Meeting fee	20,000	-
A F M Anwarul Huq	Managing Director		60,000	70,000
Ms. Aelza Yeasmin	Director		60,000	40,000
Ms. Hafiza Yeasmin	Director		100,000	100,000
Md. Shariqul Anam	Director		110,000	-
A K M Haruner Rashid, FCS	Independent Director		120,000	130,000
Md. Nazrul Islam, FCS	Independent Director		-	-
Ms. Israt Jahan Rimi, FCS	Independent Director		-	-
Fatima Parvin	Director		-	60,000
Md. Golam Kabbani	Director (Represented of ICB)		-	140,000
Ifikhar Uz zaman	Independent Director		-	30,000

33.00 The requirements of schedule XI, Part II, note-5 Para 3, of the company Act.1994.

Employees	2025	2024
Number of employees whose salary was below Tk. 3,000.00	-	-
Number of employees whose salary was above Tk. 3,000.00	127	152

34.00 Disclosure as per Schedule XI, Part – II, Para 8 of the companies Act, 1994.

a) Import of raw materials and packing materials on CIF basis are as follows:

The company import any raw and packing materials at CIF price in 2024-2025. All purchase of raw materials by the company was at C&F price.

During the period 1st July 2024 to 30th June 2025 total value of import in respect of raw materials stand equivalent USD 45,600 on CIF basis. Details are as follows:

Particulars	Amount In BDT	
	2025	2024
Import of raw Materials	6,609,474	22,417,296
Import of Packing Materials	-	6,424,400
Import of Capital goods	-	-
<b>Total:</b>	<b>6,609,474</b>	<b>28,841,696</b>

b) The Company did not incur any expenditure in foreign currency during the financial year on account of royalty, Know-how, professional Consultation fees, Interest and other matters.

(c) The value of both imported and Indigenous raw materials, Spare parts, Packing materials and Consumption thereof are as follows;



Sl.No	Particulars	Amounts in Taka	
		30 June 2025	30 June 2024

**For the year 30 June 2025**

Raw Materials:	Imported	Indigenous	Total
Opening balance	40,916,723	14,832,456	55,749,179
Add: Purchase during the year	6,609,474	34,583,207	41,192,681
	47,526,197	49,415,663	96,941,860
Less: Closing balance	-	9,409,207	9,409,207
Consumption during the year	47,526,197	40,006,456	87,532,653
Percentage of total Consumption during the year	100.00%	80.90%	90.29%

Spare Parts	Imported	Indigenous	Total
Opening balance	-	433,397	433,397
Add: Purchase during the year	-	952,560	952,560
	-	1,385,957	1,385,957
Less: Closing balance	-	921,933	921,933
Consumption during the year	-	464,024	464,024
Percentage of total Consumption during the year	0.00%	33.48%	33.48%

Packing Materials	Imported	Indigenous	Total
Opening balance	1,023,568	12,954,323	13,977,891
Add: Purchase during the year	-	21,736,266	21,736,266
	1,023,568	34,690,589	35,714,157
Less: Closing balance	-	7,110,885	7,110,885
Consumption during the year	1,023,568	27,580,504	28,604,072
Percentage of total Consumption during the year	100.00%	79.50%	80.09%

**For the year 30 June 2024**

Raw Materials:	Imported	Indigenous	Total
Opening balance	53,465,325	7,845,190	61,310,515
Add: Purchase during the year	22,417,296	69,836,802	92,254,098
	75,882,621	77,681,992	153,564,613
Less: Closing balance	40,916,723	14,832,456	55,749,179
Consumption during the year	34,965,898	62,849,536	97,815,434
Percentage of total Consumption during the year	46.08%	80.91%	63.70%

Spare Parts	Imported	Indigenous	Total
Opening balance	-	625,420	625,420
Add: Purchase during the year	-	854,350	854,350
	-	1,479,770	1,479,770
Less: Closing balance	-	433,397	433,397
Consumption during the year	-	1,046,373	1,046,373
Percentage of total Consumption during the year	-	70.71%	70.71%

Packing Materials	Imported	Indigenous	Total
Opening balance	1,235,680	17,501,134	18,736,814
Add: Purchase during the year	6,424,400	9,144,664	15,569,064
	7,660,080	26,645,798	34,305,878
Less: Closing balance	1,023,568	12,954,323	13,977,891
Consumption during the year	6,636,512	13,691,475	20,327,987
Percentage of total Consumption during the year	86.64%	51.38%	86.60%

(d) No amount was remitted during the year in foreign currencies on account of dividend to non-residents shareholders. It is mentioned that the company does not have any non-resident shareholders.

(e) Earnings in foreign exchange classified under the following heads:

Heads	30.06.2025	30.06.2024
i. Export of goods on FOB basis	Nil	Nil
ii. Royalty, know-how, professional and consultation fees	Nil	Nil
iii. Interest and dividend	Nil	Nil
iv. Other income	Nil	Nil
Total:	Nil	Nil



Sl.No	Particulars	Amounts in Taka	
		30 June 2025	30 June 2024

### 35.00 Events after the Reporting Period

The Board of Directors at its board meeting held on 15 November 2025 recommended Cash 0.15% Cash for all Shareholders of the paid up Capital for the year ended 30 June 2025. This dividend is subject to final approval by the shareholders at the forthcoming annual General Meeting (AGM) of the company.

### 36.00 Financial Risk Management

The management of company has overall for the establishment and oversight of the company's risk management framework. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. The company has exposure to the following risk for its use of financial instruments.

#### Credit Risk

#### Liquidity Risk

#### Market Risk

#### Credit Risk

Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the company's receivables. Management has a credit policy in place and exposure to credit risk monitored on an ongoing basis. As at 30th June 2022 substantial part of the receivables are those from its related company and subject to insignificant credit risk. Risk exposures from other financial assets, i.e. Cash at bank and other external receivables are nominal.

#### Liquidity Risk

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (cash and cash equivalents) is to ensure as far as possible, that it will always have sufficient liquidity to meet its liabilities when due under both normal and stressed conditions without incurring unacceptable losses or risking damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalent to meet expected operational expenses including financial obligation through preparation of the cash flow forecast with due consideration of time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date. In extreme stressed conditions the company may get support from the related company in the form of short term financing.

Trade and Other Payables (Notes: 15)

**Total**

Amounts in Taka	
30-Jun-25	30-Jun-24
18,473,871	855,971
<b>18,473,871</b>	<b>855,971</b>

#### Market Risk

Market risk is the risk that any changes in market prices such as foreign exchange rates and interest will affect the company's income or the value of its holdings financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

#### (a) Currency risk

The company is exposed to currency risk on certain revenues and purchases such as revenue from foreign customers and import of raw materials, machineries and equipment. Majority of the company's foreign currency transactions are denominated in USD and relate to procurement of raw materials, machineries and equipment from abroad.

#### (b) Interest rate risk

Interest rate risk is the risk that arises due to changes in interest rates on borrowing. The foreign currency loan is subject to floating rates of interest. Local loans are, however, not significantly affected by fluctuations in interest rate risk. The company has not entered into any type of derivative instrument in order to hedge interest rate risk as at the reporting date.

### 37.00 Compensation of Key Management Personnel

During the period, Compensation of key management personnel in total has been set below in accordance with the provisions of IAS 24: Related Party Disclosures.

Short-term employee benefits\*

Post-employment benefits

Other long-term benefits

Termination benefits

Share-based payments

**Total**

Amounts in Taka	
30-Jun-25	30-Jun-24
3,000,000	3,900,000
-	-
-	-
-	-
-	-
<b>3,000,000</b>	<b>3,900,000</b>

\*Short-term employee benefits comprise of Directors' remuneration that has been fixed up by the BOD having regard to the performance of the individuals and market trends.



**INDO-BANGLA PHARMACEUTICALS PLC**  
Schedule of Property Plant & Equipment  
As at 30th June, 2025

Annexure-A

Particulars	COST				Rate	DEPRECIATION				Written Down Value as on 30.06.2025
	Balance as on 01.07.2024	Addition during the Period	Disposal during the period	Total Cost as at 30.06.2025		Balance as on 01.07.2024	Adjusted during the period	Charge during the period	Total Cost as at 30.06.2025	
Land & Land Development	160,112,933	-	-	160,112,933	0%	-	-	-	-	160,112,933
Building	236,168,819	-	-	236,168,819	2.5%	37,756,081	4,960,318	42,716,399	42,716,399	193,452,420
Civil Works	16,082,250	6,059,503	-	22,141,753	5%	3,049,550	954,610	4,004,160	4,004,160	18,137,593
Machineries & Equipment	987,188,018	-	-	987,188,018	2%	145,678,404	16,830,192	162,508,596	162,508,596	824,679,422
Micro biological Lab	19,074,415	-	-	19,074,415	3%	2,795,793	488,359	3,284,152	3,284,152	15,790,263
Factory Air Condition	6,525,480	-	-	6,525,480	10%	3,115,371	341,011	3,456,382	3,456,382	3,069,098
Air Compressor	2,325,900	-	-	2,325,900	10%	888,895	143,700	1,032,596	1,032,596	1,293,304
Generator	10,603,229	-	-	10,603,229	3%	1,872,806	261,913	2,134,719	2,134,719	8,468,510
Sub-Station (electricity) 630 KVA	5,941,500	-	-	5,941,500	10%	99,025	584,248	683,273	683,273	5,258,228
Furniture & Fixture	14,446,419	-	-	14,446,419	10%	6,953,620	749,280	7,702,900	7,702,900	6,743,519
Office Equipment	4,962,146	-	-	4,962,146	10%	2,863,633	209,851	3,073,484	3,073,484	1,888,662
SEP Decoration	15,620,100	-	-	15,620,100	10%	7,059,244	856,086	7,915,330	7,915,330	7,704,770
Office Decoration	6,011,150	-	-	6,011,150	10%	2,504,250	350,690	2,854,940	2,854,940	3,156,210
Computer	1,307,990	-	-	1,307,990	10%	492,085	81,591	573,675	573,675	734,315
Air Condition	354,170	-	-	354,170	10%	187,708	16,646	204,354	204,354	149,816
Transport	23,253,762	-	-	23,253,762	10%	9,487,209	1,376,655	10,863,865	10,863,865	12,389,897
Water Plant	2,512,960	-	-	2,512,960	10%	1,563,727	94,923	1,658,650	1,658,650	854,310
ETP Plant	1,945,375	-	-	1,945,375	10%	1,189,335	75,604	1,264,939	1,264,939	680,436
Balance as on 30 June,2025	1,514,436,616	6,059,503	-	1,520,496,119		227,556,737	-	255,932,414	255,932,414	1,264,563,705
Balance as on 30 June,2024	1,514,436,616	-	-	1,514,436,616		199,013,270	-	227,556,737	227,556,737	1,286,879,880

**Intangible Assets**

Particulars	Balance as on 01.07.2024	Addition	Disposal	Total Cost as at 30.06.2025	Rate	Balance as on 01.07.2024	Adjusted	Charge during the period	Total Cost as at 30.06.2025	WDV as on 30.06.2025
Accounting Software	-	560,000	-	560,000	0	-	-	84,000	84,000	476,000

**Allocation of Depreciation**

Factory	Administration
24,734,878	3,640,799
28,375,677	

